<DOC>
	<DOCNO>NCT00659425</DOCNO>
	<brief_summary>To estimate maximum cummulative dose ( MTCD ) CAT-8015 safely administer patient .</brief_summary>
	<brief_title>CAT-8015 Children , Adolescents Young Adults With Acute Lymphoblastic Leukemia Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>To estimate maximum tolerated cummulative dose ( MTCD ) , define high dose number dos safely administer patient , establish safe dose , base MTCD , subsequent clinical testing .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Histologically confirm diagnosis acute lymphoblastic leukemia ( ALL ) nonHodgkin 's lymphoma ( NHL ) include lymphoblastic lymphoma , Burkitt 's lymphoma , large cell lymphoma ; Measurable evaluable disease . Subjects ALL M2 M3 bone marrow classification ; Evidence CD22positive malignancy one follow criterion : ≥ 30 % malignant cell disease site CD22+ fluorescenceactivated cell sorter ( FACS ) analysis ; ≥ 15 % malignant cell disease site CD22+ immunohistochemistry ( IHC ) . Stage disease : Subjects must relapse refractory disease receive least one standard chemotherapy one salvage regimen allogeneic stem cell transplant ; In view PI primary oncologist , must available alternative curative therapy subject must either ineligible hematopoietic stem cell transplant ( HSCT ) , refuse HSCT , disease activity prohibit HSCT time ; Relapse prior autologous allogeneic HSCT allow . In event relapse prior allogeneic HSCT , subject must least 100 day posttransplant evidence ongoing active graftvshost disease ; Recovered acute toxic effect prior therapy entry . Performance status : Subjects great equal 12 year age : Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 , 2 , 3 ; Subjects &lt; 12 year age : Lansky scale ≥ 50 % ; Subjects unable walk paralysis , wheel chair consider ambulatory purpose calculate performance score . Subjects follow CNS status , eligible absence neurologic symptom suggestive CNS leukemia , cranial nerve palsy : CNS 1 , define absence blast cerebral spinal fluid ( CSF ) cytospin preparation , regardless number WBCs ; CNS 2 , define presence &lt; 5/µL WBCs CSF cytospin positive blast , &gt; 5/µL WBCs negative Steinherz/Bleyer algorithm : CNS 2a : &lt; 10/µL RBCs ; &lt; 5/µL WBCs cytospin positive blast ; CNS 2b : ≥ 10/µL RBCs ; &lt; 5/µL WBCs cytospin positive blast ; CNS 2c : ≥ 10/µL RBCs ; ≥ 5/µL WBCs cytospin positive blast negative Steinherz/Bleyer algorithm . Ability give inform consent accord applicable regulatory state requirement . In United States : For subject &lt; 18 year old legal guardian must give informed consent . Pediatric subject include age appropriate discussion verbal assent obtain ≥ 7 year age ; Must age great equal 6 month &lt; 25 year ; Female male subject childbearing potential sexual partner must agree use approve method contraception study . Subjects meet follow criterion eligible participation study : Isolated testicular Central Nervous System ( CNS ) ALL ; Hepatic function : Inadequate liver function define total bilirubin &gt; 2 × upper limit normal ( ULN ) ( except case subject document Gilbert 's disease &gt; 5 × ULN ) transaminases ( ALT aspartate aminotransferase [ AST ] ) &gt; 5 × ULN base age laboratoryspecific normal range ; Renal function : With great ageadjusted normal serum creatinine ( see Table ) creatinine clearance &gt; 60 mL/min/1.73 m2 . Age ( Years ) Maximum Serum Creatinine ( mg/dl ) [ ≤5,0.8 ] [ 5 &lt; age less equal 10,1.0 ] [ 10 &lt; age less equal 15,1.2 [ &gt; 15 , 1.5 ] Hematologic function : For nonleukemic subject , absolute neutrophil count ( ANC ) &lt; 1000/cmm , platelet count &lt; 50,000/cmm , cytopenia judge investigator due underlying disease ( ie potentially reversible antineoplastic therapy ) ; A subject exclude pancytopenia ≥ Grade 3 due disease , base result bone marrow study ; Subjects CNS 3 disease ( presence ≥ 5/µL WBCs CSF cytospin positive blast [ absence traumatic lumbar puncture ] and/or clinical sign CNS leukemia ) ; Radiologicallydetected CNS lymphoma ; Laboratory finding consistent Grade ≥ 3 disseminate intravascular coagulation ( DIC ) Grade 2 DIC correct ; Hyperleukocytosis ( ≥ 50,000 blasts/µL ) rapidly PD estimation investigator sponsor would compromise ability complete study therapy ; Pregnant breastfeeding female ; Prior treatment CAT3888 ( BL22 ) pseudomonasexotoxincontaining compound ; Recent prior therapy : Systemic chemotherapy ≤ 2 week ( 6 week nitrosoureas ) radiation therapy ≤ 3 week prior start study drug ; Exceptions : 1 . There time restriction regard prior intrathecal chemotherapy provide complete recovery acute toxic effect ; 2 . Subjects receive corticosteroid hydroxyurea allow provided increase dose least 2 week prior start study drug ; 3 . For radiation therapy : volume bone marrow treat less 10 % also subject measurable disease outside radiation port ; 4 . Subjects relapse receive standard ALL maintenance chemotherapy require washout period entry study . Other investigational agent currently within 30 day prior entry ; Less equal 1 month prior monoclonal antibody therapy ( eg , rituximab ) . Subjects contraindication corticosteroid administration ; HIV positive serology ( due increase risk severe infection unknown interaction CAT8015 antiretroviral drug ) ; Active hepatitis B C infection define seropositive hepatitis B ( hepatitis B surface antigen [ HBsAg ] ) hepatitis C elevate liver transaminase ( define ULN per institution normal range ) ; Uncontrolled , symptomatic , intercurrent illness include limited infection , congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness , malaria infection , social situation would limit compliance study requirement ; Second malignancy nonbasal cell carcinoma skin situ carcinoma cervix , unless tumor treat curative intent least two year previously subject remission . Any physical , social , psychiatric condition opinion investigator would prevent effective cooperation participation study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>